John Rim, CEO of Samsung Biologics, said in a New Year's address on the 2nd that the company will strengthen its position as a trusted contract development and manufacturing organization (CDMO) partner and will reinforce its ultra-wide competitive edge by expanding production capacity, its portfolio, and global footholds.
John Rim said that this year the environment surrounding the company will not be easy and high standards will be required in every aspect, adding that customer satisfaction cannot be overemphasized. He also said that quality is the foundation of the bio industry, which deals with life, and must be upheld without compromise under any circumstances, and that the company will improve operational efficiency with artificial intelligence (AI) and invest in talent development to build the capabilities of employees.
He said the company must remove unnecessary complexity through simplification and increase the speed of decision-making and execution, and that it must secure consistent quality at all times through standardization. He added that, to respond flexibly to rapidly changing markets and customer demands, the company should pursue a growth strategy based on scalability.
John Rim said the company completed a spin-off last year, secured a site for the Third Bio Campus in Songdo, and acquired a plant in Rockville, the United States, adding that it will advance its antibody-drug conjugate (ADC) and Organoid (mini organ) businesses and develop them into key pillars supporting future growth. He continued that this year marks the 15th anniversary of the company's founding and the Year of the Red Horse, and said he hopes the company will leap toward its goal of becoming the No. 1 global CDMO, like the horse that symbolizes tireless passion and drive.